EUVIMEDEUVIMED entdecken
Crossref

Tumor lysis syndrome

Beyza Hilal Balcı, Selim Yalçın

Ankyra Medical Journal · 25.03.2026 · 5 (2) · 50-55

DOI: 10.51271/ankmj-0066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ankyra Medical Journal, online erschienen am 25.03.2026. Verfasst von Beyza Hilal Balcı und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor lysis syndrome is defined as the release of intracellular metabolites into the bloodstream, resulting from the breakdown of tumor cells due to various causes encountered in clinical practice. It has been observed that tumor lysis syndrome, which occurs in patients with existing malignancy, further worsens the prognosis in the already poor condition and increases the risk of mortality in patients. Therefore, the diagnosis and follow-up of tumor lysis syndrome by relevant clinicians is of great importance. This review examines overlooked aspects of tumor lysis syndrome, including its etiology, pathophysiology, necessary investigations, diagnosis, treatment algorithms, and current clinical approach.

Zitieren

APA

Balcı, B. H., & Yalçın, S. (2026). Tumor lysis syndrome. Ankyra Medical Journal, 5(2), 50-55. https://doi.org/10.51271/ankmj-0066

Vancouver

Balcı BH, Yalçın S. Tumor lysis syndrome. Ankyra Medical Journal. 2026;5(2):50-55. doi:10.51271/ankmj-0066

BibTeX
@article{Balc2026,
  author = {Balcı, Beyza Hilal and Yalçın, Selim},
  title = {Tumor lysis syndrome},
  journal = {Ankyra Medical Journal},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {50--55},
  doi = {10.51271/ankmj-0066}
}
Kostenlos starten →